FFS
NVO

Founders Financial Securities’s Novo Nordisk NVO Stock Holding History

Founders Financial Securities’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-7,688
Closed -$531K – 515
2025
Q2 		$531K Sell
7,688
-44
-0.6% -$2.99K 0.04% 333
2025
Q1 		$484K Buy
7,732
+4,220
+120% +$349K 0.04% 321
2024
Q4 		$302K Buy
3,512
+1,735
+98% +$188K 0.03% 379
2024
Q3 		$212K Sell
1,777
-1,932
-52% -$258K 0.02% 406
2024
Q2 		$529K Buy
3,709
+2,017
+119% +$267K 0.05% 277
2024
Q1 		$217K Buy
+1,692
New +$201K 0.02% 355
2017
Q4 		– Sell
-22,066
Closed -$531K – 103
2017
Q3 		$531K Sell
22,066
-21,468
-49% -$485K 0.19% 70
2017
Q2 		$934K Sell
43,534
-1,050
-2% -$21.2K 0.36% 45
2017
Q1 		$764K Buy
44,584
+23,942
+116% +$417K 0.29% 55
2016
Q4 		$370K Buy
+20,642
New +$374K 0.15% 65

Other funds holding NVO

Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
Fayez Sarofim & Co
Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Founders Financial Securities's NVO Position: Q3 2025 in Review

Founders Financial Securities sold out of Novo Nordisk (NVO) in Q3 2025, closing a stake of 7,688 shares — an estimated $531K sold.

Founders Financial Securities first reported a position in NVO in Q4 2016 and held it in 10 quarters. The position peaked at $934K in Q2 2017. 1,395 funds tracked by Wall St. Rank hold NVO as of Q3 2025.

  • Founders Financial Securities reported no remaining Novo Nordisk position as of Q3 2025 after selling out during the quarter.
  • Founders Financial Securities sold 7,688 Novo Nordisk shares in Q3 2025, an estimated $531K.
  • Founders Financial Securities first reported a position in Novo Nordisk in Q4 2016 and held it in 10 quarters.
  • Founders Financial Securities's Novo Nordisk position peaked at $934K in Q2 2017.
  • 1,395 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2025.

Based on Founders Financial Securities's 13F filing for Q3 2025, filed 15 Oct 2025.